<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Innovation Funding and Crown Bioscience: Collaborating to Discover the Next Wave of Oncology Therapies

Leiden, Netherlands—May 23, 2024. Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced its pivotal role in several scientific innovation projects funded by European grants. These projects aim to advance cancer treatments and the development of the tools to do so, employing cutting-edge techniques such as organoid and ex vivo patient tissue technologies, with the goal of bridging the gap between research and patient care. With collaborative efforts among small and medium-sized businesses, academic institutions, and enterprise companies, these initiatives will enhance R&D partnerships and advance the development and commercialization of lead compounds and novel oncology therapeutics.

The portfolio includes the first-in-class LIPIDOMAB project*, a novel initiative in advanced cancer therapy backed by a €3 million grant from the Eurostars-Eureka program. Crown Bioscience and its partners, ONA Therapeutics SL, Ariana Pharmaceuticals, and oloBion SLU, aim to combat cancer progression with an anti-CD36 therapeutic antibody. Launched in October 2023, this two-year project seeks to decode the antibody's mechanism of action through organoid, lipidomics, and Ariana’s KEM® eXplainable AI technology. Crown Bioscience will utilize and advance its OrganoidXploreTM panel screening capabilities to expedite the development of new patient-derived tumor and metastasis-derived organoids with matched immune components in an autologous co-culture system. The project’s objective is to identify novel biomarkers that could influence patient stratification and the design and development of clinical trials—potentially leading to companion diagnostics (CDx).

Adding breadth to Crown Bioscience’s innovation initiatives are several more EU-funded projects, each pledged to facilitate scientific research, job creation, and overall growth:

  • LEFTY Project*: Partnered with Onena Medicines, Cancer Research Center Lyon, and HAWK Biosystems, this initiative focuses on countering therapeutic resistance in solid cancers using a monoclonal antibody (mAb-LEFTY1). Initiated in March 2023 with €1.8 million in support, the project aims to develop and expand Crown Bioscience’s organoid panel screening capabilities for the characterization of standard of care compounds and mAb-LEFTY1 drug responses, along with the development of CRISPR-edited drug-resistant organoid models.

  • GLIOPEP Project*: In collaboration with Oncopeptides AB, Uppsala University, and Xenopat, this €1.8 million funded project aims to develop a pioneering tumor-directed chemotherapy for glioblastoma (GBM) patients based on Oncopeptides´ proprietary PDC platform. Also started in March 2023, this project involves Crown Bioscience in the creation of advanced patient-derived in vitro GBM models, including ex vivo patient tissue-based assays and organotypic cultures.

  • Ab-SENS Project*: This project, which began in June 2022 with a €3 million allocation, seeks to pioneer cancer therapy by developing a monoclonal antibody and a diagnostic tool targeting senescence. Together with Rejuveron Senescence Therapeutics and Screenin3D, Crown Bioscience is striving to enhance tumor organoid co-cultures and delve into senescence within its organoid platform.

  • DRUGTrain Project: Supported by a €2.4 million grant from Marie Skłodowska-Curie Innovative Training Networks, this project focuses on drug repurposing and discovery targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD). Having commenced in November 2021, Crown Bioscience, along with European partners; Leiden University Medical Center (coordinator), Janssen Pharmaceutica, Universidad Santiago de Compostela, Universitat Konstanz, Universitet Uppsala, University of Manchester, and Universitätsklinikum Aachen, plays a key role. Crown Bioscience’s contribution has been central in developing new scientific leaders and advancing the PKD platform, including the development of a smFISH platform.

Crown Bioscience’s active participation in these high-impact projects underscores its unwavering dedication to scientific excellence, and the mission to help customers develop novel therapies aims to ensure that patients receive the right treatment at the right time.

Visit the Crown Bioscience website for more insight into the innovative platforms and services available.

* Eurostars-Eureka-funded project

Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell

Upcoming Events

Bio 2024

June 3-6, 2024|San Diego, CA | Booth #5327

Register Now